GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » Investments And Advances

Frontage Holdings (HKSE:01521) Investments And Advances : HK$0 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings Investments And Advances?

Frontage Holdings's Investments And Advances for the quarter that ended in Dec. 2024 was HK$0 Mil.


Frontage Holdings Investments And Advances Historical Data

The historical data trend for Frontage Holdings's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings Investments And Advances Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only - - - - -

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Frontage Holdings Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Frontage Holdings Business Description

Traded in Other Exchanges
N/A
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
Executives
Li Song 2101 Beneficial owner
Hongkong Tigermed Co., Limited
Hang Zhou Tai Ge Yi Yao Ke Ji Gu Fen You Xian Gong Si 2101 Beneficial owner
Kabouter Management Llc 2102 Investment manager
Hangzhou Tigermed Consulting Co., Ltd.

Frontage Holdings Headlines

No Headlines